Idera Pharmaceuticals Announces Publication of Preclinical Data on Toll-Like Receptor 7 and 8 Agonists
14 Août 2007 - 2:00PM
Business Wire
Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced the
publication of preclinical data on its stabilized immune modulatory
RNA (SIMRA) compounds that act as agonists of Toll-Like Receptors
(TLR) 7 and 8. In this publication, data were reported from
preclinical studies in human cell-based assays and in vivo in
non-human primates in which SIMRA compounds induced immune
responses. In the reported data the agonistic activity for TLR 7
and 8 was dependent on the chemical composition of the SIMRA
compounds. The paper entitled �Stabilized immune modulatory RNA
compounds as agonists of Toll-like receptors 7 and 8� is published
in the Proceedings of National Academy of Sciences, U.S.A. (Vol.
104: 13750-13755, 2007). The authors of the paper are Tao Lan,
Ekambar R. Kandimalla, Dong Yu, Lakshmi Bhagat, Yukui Li, Daqing
Wang, FuGang Zhu, Jimmy X. Tang, Mallikarjuna R. Putta, YanPing
Cong, Anthony F. Trombino, Tim Sullivan, and Sudhir Agrawal of
Idera. �Using our extensive experience in nucleic acid chemistry,
we have designed SIMRA compounds to mimic viral RNA as agonists to
TLRs 7 and 8,� said Sudhir Agrawal, D. Phil., Chief Executive
Officer and Chief Scientific Officer. �These SIMRA compounds add to
our diverse portfolio of proprietary TLR-targeted compounds with
potential applications in oncology and infectious diseases and as
vaccine adjuvants under our collaboration with Merck and Co., Inc.�
About Idera Pharmaceuticals, Inc. Idera Pharmaceuticals is a drug
discovery and development company that is developing drug
candidates to treat cancer and infectious, respiratory, and
autoimmune diseases, and for use as vaccine adjuvants. Idera�s
proprietary drug candidates are designed to modulate specific TLRs,
which are a family of immune system receptors. Idera�s pioneering
DNA chemistry expertise enables it to identify drug candidates for
internal development and creates opportunities for multiple
collaborative alliances. Idera�s most advanced clinical candidate,
IMO-2055, is an agonist of TLR9 and is currently in a Phase 2 trial
in oncology and in a Phase 1/2 chemotherapy combination trial in
oncology. Idera has filed an Investigational New Drug application
on a second TLR9 agonist, IMO-2125, for treatment of hepatitis C
virus infection. Idera is collaborating with Novartis International
Pharmaceutical, Ltd. for the discovery, development, and
commercialization of TLR9 agonists for the treatment of asthma and
allergy indications. Idera is also collaborating with Merck &
Co., Inc. for the use of Idera�s TLR7, 8 and 9 agonists in
combination with Merck�s therapeutic and prophylactic vaccines in
the areas of oncology, infectious diseases, and Alzheimer�s
disease. For more information, visit www.iderapharma.com. Forward
Looking Statements This press release contains forward-looking
statements concerning Idera Pharmaceuticals, Inc. that involve a
number of risks and uncertainties. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed to be forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"estimates," "intends," "should," "could," "will," "may," and
similar expressions are intended to identify forward-looking
statements. There are a number of important factors that could
cause Idera�s actual results to differ materially from those
indicated by such forward-looking statements, including whether
results obtained in early clinical studies or in preclinical
studies such as the studies referred to above will be indicative of
results obtained in future clinical trials or warrant additional
trials; whether products based on Idera�s technology will advance
into or through the clinical trial process on a timely basis or at
all and receive approval from the United States Food and Drug
Administration or equivalent foreign regulatory agencies; whether,
if the Company�s products receive approval, they will be
successfully distributed and marketed; whether the Company�s
collaborations with Novartis and Merck will be successful; whether
Idera�s cash resources will be sufficient to fund product
development and clinical trials; and such other important factors
as are set forth under the caption "Risk Factors" in Idera�s
Quarterly Report on Form 10-Q filed on August 1, 2007, which
important factors are incorporated herein by reference. Idera
disclaims any intention or obligation to update any forward-looking
statements.
Idera Pharmaceutical (AMEX:IDP)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Idera Pharmaceutical (AMEX:IDP)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024